fluoxetine has been researched along with Diabetes Mellitus, Type 2 in 29 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine and Citalopram can effectively reduce the severity of depression in diabetic patients without an adverse effect on glycemic control." | 9.15 | Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? ( Khazaie, H; Najafi, F; Rahimi, M; Rezaei, M; Tahmasian, M; Tatari, F, 2011) |
| "Reduction in depression symptoms was significantly greater in patients treated with fluoxetine compared with those receiving placebo (BDI, -14." | 9.09 | Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. ( Clouse, RE; Freedland, KE; Griffith, LS; Lustman, PJ, 2000) |
| "To study the effect of fluoxetine, a specific serotonin reuptake inhibitor, on insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) independently of its action on body weight." | 9.08 | Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997) |
| "The metformin treatment counteracted the development of depression-like behaviors in mice suffering SDS when administered alone and enhanced the anti-depressant effect of fluoxetine when combined with fluoxetine." | 7.96 | Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation. ( Chen, X; Dai, X; Fang, W; Hong, L; Huang, W; Ye, Q; Zhang, J, 2020) |
| "Fluoxetine (F) is a specific serotonin-reuptake inhibitor that has been shown to promote weight loss and improve glycemic control in obese diabetic patients." | 6.68 | Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. ( Astrup, A; Bak, JF; Bjerre, U; Breum, L; Jacobsen, S, 1995) |
| "Fluoxetine and Citalopram can effectively reduce the severity of depression in diabetic patients without an adverse effect on glycemic control." | 5.15 | Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? ( Khazaie, H; Najafi, F; Rahimi, M; Rezaei, M; Tahmasian, M; Tatari, F, 2011) |
| "Reduction in depression symptoms was significantly greater in patients treated with fluoxetine compared with those receiving placebo (BDI, -14." | 5.09 | Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. ( Clouse, RE; Freedland, KE; Griffith, LS; Lustman, PJ, 2000) |
| "To study the effect of fluoxetine, a specific serotonin reuptake inhibitor, on insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) independently of its action on body weight." | 5.08 | Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997) |
| "Fluoxetine, an inhibitor of serotonin re-uptake, has been shown to cause weight loss in humans and animals." | 5.07 | Fluoxetine treatment of the obese diabetic. ( Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992) |
| "Short period of fluoxetine therapy can lead to weight loss as well as reduction of FPG, HbA1c and TG in T2DM." | 4.87 | Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. ( Chen, L; He, M; Hu, J; Hu, R; Huang, Y; Li, Q; Liu, C; Qu, S; Wang, X; Yang, Z; Ye, Z; Zhang, S; Zhang, Z; Zhao, W, 2011) |
| "Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 26 to 52 weeks." | 4.82 | Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. ( Avenell, A; Gregg, E; Kim, C; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2004) |
| "Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks." | 4.82 | Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. ( Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2005) |
| "The metformin treatment counteracted the development of depression-like behaviors in mice suffering SDS when administered alone and enhanced the anti-depressant effect of fluoxetine when combined with fluoxetine." | 3.96 | Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation. ( Chen, X; Dai, X; Fang, W; Hong, L; Huang, W; Ye, Q; Zhang, J, 2020) |
| "Fluoxetine (F) is a specific serotonin-reuptake inhibitor that has been shown to promote weight loss and improve glycemic control in obese diabetic patients." | 2.68 | Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. ( Astrup, A; Bak, JF; Bjerre, U; Breum, L; Jacobsen, S, 1995) |
| "Weight reduction is essential in the management of most non-insulin-dependent diabetics, but this therapeutical goal is difficult to obtain." | 2.68 | Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. ( Daubresse, JC; Kolanowski, J; Krzentowski, G; Kutnowski, M; Scheen, A; Van Gaal, L, 1996) |
| "When nondiabetics and NIDDM were considered together, only the most insulin-resistant individuals demonstrated a decrease in ED50pgu (P less than 0." | 2.67 | Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. ( Frölich, M; Krans, HM; Meinders, AE; Potter van Loon, BJ; Radder, JK; Zwinderman, AH, 1992) |
| "Fluoxetine is an inhibitor of serotonin re-uptake which has been found to produce weight loss in humans and animals." | 2.67 | A randomized double-blind clinical trial of fluoxetine in obese diabetics. ( Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (41.38) | 18.2507 |
| 2000's | 7 (24.14) | 29.6817 |
| 2010's | 5 (17.24) | 24.3611 |
| 2020's | 5 (17.24) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, Z | 1 |
| Jia, Y | 1 |
| Zhao, L | 1 |
| Zhu, R | 1 |
| He, X | 1 |
| Tong, B | 1 |
| Yang, F | 1 |
| Hao, L | 1 |
| Cui, P | 1 |
| Yuan, J | 1 |
| Zhang, Z | 2 |
| Du, Y | 1 |
| Chen, L | 2 |
| Liu, Y | 1 |
| Du, B | 1 |
| Cao, TXD | 1 |
| Filliter, C | 1 |
| Montastruc, F | 1 |
| Yu, OHY | 1 |
| Fergusson, E | 1 |
| Rej, S | 1 |
| Azoulay, L | 1 |
| Renoux, C | 1 |
| Fang, W | 1 |
| Zhang, J | 1 |
| Hong, L | 1 |
| Huang, W | 1 |
| Dai, X | 1 |
| Ye, Q | 1 |
| Chen, X | 1 |
| Yang, H | 1 |
| Cao, Q | 1 |
| Xiong, X | 1 |
| Zhao, P | 1 |
| Shen, D | 1 |
| Zhang, Y | 1 |
| Zhang, N | 1 |
| De Long, NE | 1 |
| Barry, EJ | 1 |
| Pinelli, C | 1 |
| Wood, GA | 1 |
| Hardy, DB | 1 |
| Morrison, KM | 1 |
| Taylor, VH | 1 |
| Gerstein, HC | 1 |
| Holloway, AC | 1 |
| Khazaie, H | 1 |
| Rahimi, M | 1 |
| Tatari, F | 1 |
| Rezaei, M | 1 |
| Najafi, F | 1 |
| Tahmasian, M | 1 |
| Ye, Z | 1 |
| Yang, Z | 1 |
| Li, Q | 1 |
| Huang, Y | 1 |
| He, M | 1 |
| Zhang, S | 1 |
| Wang, X | 1 |
| Zhao, W | 1 |
| Hu, J | 1 |
| Liu, C | 1 |
| Qu, S | 1 |
| Hu, R | 1 |
| Kachowski, L | 1 |
| Over, DR | 1 |
| Qiu, K | 1 |
| Tissot, TA | 1 |
| Norris, SL | 2 |
| Zhang, X | 2 |
| Avenell, A | 2 |
| Gregg, E | 2 |
| Schmid, CH | 2 |
| Kim, C | 1 |
| Lau, J | 2 |
| Choi, JS | 1 |
| Han, JY | 1 |
| Ahn, HK | 1 |
| Shin, JS | 1 |
| Yang, JH | 1 |
| Koong, MK | 1 |
| Nava-Ocampo, AA | 1 |
| Toubro, S | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Connolly, VM | 1 |
| Gallagher, A | 1 |
| Kesson, CM | 1 |
| Holman, SL | 1 |
| Goldstein, DJ | 1 |
| Enas, GG | 1 |
| Deeg, MA | 1 |
| Lipkin, EW | 1 |
| Breum, L | 1 |
| Bjerre, U | 1 |
| Bak, JF | 1 |
| Jacobsen, S | 1 |
| Astrup, A | 1 |
| Daubresse, JC | 1 |
| Kolanowski, J | 1 |
| Krzentowski, G | 1 |
| Kutnowski, M | 1 |
| Scheen, A | 1 |
| Van Gaal, L | 1 |
| Chin, CK | 1 |
| Roe, CJ | 1 |
| Thomas, GW | 1 |
| Maheux, P | 1 |
| Ducros, F | 1 |
| Bourque, J | 1 |
| Garon, J | 1 |
| Chiasson, JL | 1 |
| Fernández López, MI | 1 |
| Sánchez Esteban, J | 1 |
| Jímenez Belló, J | 1 |
| Meseguer Zaragoza, A | 1 |
| Lustman, PJ | 1 |
| Freedland, KE | 1 |
| Griffith, LS | 1 |
| Clouse, RE | 1 |
| Potter van Loon, BJ | 1 |
| Radder, JK | 1 |
| Frölich, M | 1 |
| Krans, HM | 1 |
| Zwinderman, AH | 1 |
| Meinders, AE | 2 |
| Gray, DS | 2 |
| Fujioka, K | 2 |
| Devine, W | 2 |
| Bray, GA | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Program ACTIVE: Implementing a Cognitive Behavioral Therapy and Physical Activity Program for Black Men With Comorbid Diabetes and Depression[NCT04369001] | 0 participants (Actual) | Interventional | 2020-12-31 | Withdrawn (stopped due to Due to covid-19 and social distancing, this study was terminated.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluoxetine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of the selective serotonin reuptake inhibitor fluoxetine on glucose metabolism: A systematic review.
Topics: Antidepressive Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fluoxetine; Glucose; H | 2022 |
Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.
Topics: Anti-Obesity Agents; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Fluoxetine; Gly | 2011 |
Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Dru | 2004 |
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetin | 2005 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
Very low calorie diets and recently developed anti-obesity drugs for treating overweight in non-insulin-dependent diabetics.
Topics: Adrenergic beta-Agonists; Diabetes Mellitus, Type 2; Diet, Reducing; Fenfluramine; Fluoxetine; Human | 1990 |
11 trials available for fluoxetine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
Topics: Acetamides; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Depression; Diabetes Melli | 2021 |
Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram?
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Chi-Square Distribution; Cital | 2011 |
A study of fluoxetine in obese elderly patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Evaluation S | 1995 |
Pattern analysis method for assessing successful weight reduction.
Topics: Adult; Aged; Blood Pressure; Confidence Intervals; Counseling; Diabetes Mellitus, Type 2; Double-Bli | 1994 |
Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.
Topics: Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Fluoxetine; Glucose Intol | 1995 |
Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dou | 1996 |
Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluoxetine | 1997 |
Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Depression; Diabetes Mellitus, | 2000 |
Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluoxetine; Glucose; Humans; Insu | 1992 |
Fluoxetine treatment of the obese diabetic.
Topics: Adult; Blood Glucose; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blin | 1992 |
A randomized double-blind clinical trial of fluoxetine in obese diabetics.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Femal | 1992 |
12 other studies available for fluoxetine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths.
Topics: Adolescent; Antipsychotic Agents; Citalopram; Diabetes Mellitus, Type 2; Fluoxetine; Fluvoxamine; Hu | 2022 |
Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation.
Topics: Acetylation; AMP-Activated Protein Kinases; Animals; Antidepressive Agents; Brain-Derived Neurotroph | 2020 |
Fluoxetine regulates glucose and lipid metabolism via the PI3K‑AKT signaling pathway in diabetic rats.
Topics: Animals; Cell Line; Chromones; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fluoxetin | 2020 |
In This Issue of
Topics: Adipose Tissue; Animals; Cell Membrane; Diabetes Mellitus, Type 2; Diabetic Foot; Fluoxetine; Glucos | 2019 |
Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats.
Topics: Adiposity; Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Chemokine CCL2; Diabetes | 2015 |
FPIN’s clinical inquiries. Medications for weight loss in patients with type 2 diabetes mellitus.
Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetine; Fructose; Humans; Lactones | 2012 |
Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.
Topics: Adult; Analgesics, Opioid; Cholangiopancreatography, Endoscopic Retrograde; Diabetes Mellitus, Type | 2003 |
Exposure to rosiglitazone and fluoxetine in the first trimester of pregnancy.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fluoxetine; Humans; Hypoglycemic Agents; Infant; Infant, N | 2006 |
[Pharmacotherapy for weight loss in patients with type 2 diabetes].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based M | 2007 |
Hypoglycemia associated with the use of fluoxetine.
Topics: Antidepressive Agents, Second-Generation; Depression; Diabetes Mellitus, Type 2; Fluoxetine; Humans; | 1996 |
Fluoxetine: a treatment option for severe symptomatic postural hypotension in a diabetic haemodialysis patient.
Topics: Diabetes Mellitus, Type 2; Fluoxetine; Humans; Hypotension, Orthostatic; Male; Middle Aged; Renal Di | 1996 |
[Suggestive episodes of hypoglycemia related to fluoxetine].
Topics: Adult; Diabetes Mellitus, Type 2; Diagnosis, Differential; Dizziness; Female; Fluoxetine; Humans; Hy | 1996 |